Reference
Cortese A, et al. Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases. Multiple Sclerosis and Related Disorders 35: 193-195, Oct 2019. Available from: URL: http://doi.org/10.1016/j.msard.2019.08.006 - Italy
Rights and permissions
About this article
Cite this article
Adalimumab/golimumab. Reactions Weekly 1771, 18 (2019). https://doi.org/10.1007/s40278-019-67837-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-67837-2